Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster lunch

1497 - The Possibility of Omitting Axillary Clearance by using Indocyanine Green Fluorescence Method in Detection of Sentinel Lymph Nodes in Early-stage Breast Cancer (65P)


18 Nov 2017


Poster lunch


Staging Procedures (not Imaging);  Breast Cancer


Yurina Maeshima


Annals of Oncology (2017) 28 (suppl_10): x16-x24. 10.1093/annonc/mdx655


Y. Maeshima, A. Oobayashi, R. Katsuragi, Y. Yoshimoto, S. Takahara, A. Yamauchi

Author affiliations

  • Breast Surgery, Kitano Hospital The Tazuke Kofu Kai Medical Research Institute, 530-8480 - Osaka/JP


Abstract 1497


The AMAROS trial and the ACOSOG Z0011 trial showed that axillary lymph node dissection (ALND) could be spared in certain breast cancer patients with sentinel lymph node (SLN) metastasis on condition with treatment by axillary radiotherapy and adjuvant systemic therapy. Sugie et al. reported that the indocyanine green (ICG) fluorescence method had a high SLN identification rate and a high number of SLNs. They founded that positive SLN was usually identified within the first 4 resected SLNs, which could safely replace axillary clearance for surgeons otherwise willing to perform further axillary treatment. However, the data of long-time observation of the ICG fluorescence method was few. We report the axillary recurrence rate and the rate of lymphedema after SLN biopsy using ICG fluorescence method to investigate to the possibility of sparing an ALND without residual positive nodes in axilla.


From May 2011 to December 2015, a total of 500 patients (511 axillas) with clinically node-negative breast cancer were received SLN biopsy using combination with ICG fluorescence and radioisotope, and we analyzed 493 axilla.


The median number of resected SLNs was 4.27, and median number of positive SLN nodes was 0.23. Median follow-up duration was 41 months, and axillary recurrence occurred in 5 of 493 axillas (1.01%). Four patients in the SLN positive group were not conducted the standard adjuvant therapy because of patient’s preference. Seventy-eight patients had positive SLNs, and median number of positive SLNs in 78 patients was 2.39. Although ALND was omitted for all patients, the axillary recurrence was 2 of 78 patients (2.56%), all of whom adjuvant therapy were insufficient. Lymphedema after SLN biopsy occurred in 6 patients (1.2%), but all of them had low grade.


Our data indicate that by SLN biopsy using ICG fluorescence method, the axially recurrence rate is low when treated with appropriate adjuvant therapy. Because positive SLN was usually identified within the first 4 resected SLNs, the axillary recurrence rate was low by resecting 4 SLNs, which suggests the possibility of omitting ALND without lymphedema.

Clinical trial identification

Legal entity responsible for the study

Akira Yamauchi




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.